Hutchison China MediTech Limited Share Price London S.E.
Equities
KYG4672N1198
Pharmaceuticals
Sales 2024 * | 686M 0 54.64B | Sales 2025 * | 842M 0 67.09B | Capitalization | 3.76B 0 299B |
---|---|---|---|---|---|
Net income 2024 * | -107M - -8.52B | Net income 2025 * | -2M - -159M | EV / Sales 2024 * | 5.19 x |
Net cash position 2024 * | 199M 0 15.81B | Net cash position 2025 * | 306M 0 24.34B | EV / Sales 2025 * | 4.1 x |
P/E ratio 2024 * |
-32.5
x | P/E ratio 2025 * |
684
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.37% |
Latest transcript on Hutchison China MediTech Limited
Managers | Title | Age | Since |
---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 31/12/04 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 30/06/08 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/12/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chi Keung To
CHM | Chairman | 72 | 31/12/99 |
Graeme Jack
BRD | Director/Board Member | 73 | 28/02/17 |
Dan Eldar
BRD | Director/Board Member | 70 | 31/07/16 |
1st Jan change | Capi. | |
---|---|---|
+29.39% | 684B | |
+30.34% | 568B | |
-4.02% | 361B | |
+17.79% | 329B | |
+3.97% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+6.82% | 166B |